LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance

U.S. Markets close in 4 hrs 8 mins

Eli Lilly and Company (LLY)

NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
66.76-0.62 (-0.92%)
As of 11:52 AM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close67.38
Bid66.78 x 300
Ask66.79 x 100
Day's Range66.39 - 67.07
52 Week Range64.18 - 87.21
Avg. Volume5,381,323
Market Cap70.45B
PE Ratio (TTM)29.04
Earnings DateN/A
Dividend & Yield2.04 (3.03%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com1 hour ago

    Why Biotech is Getting Killed…And Why It WIll Bounce Back

    RBC's Michael Yee and team explain why biotech stocks have been getting killed (Hint: It's not just Donald Trump)...and why they should bounce back: The primary issues we see going on and causing a lack ...

  • American City Business Journals2 hours ago

    Can Biogen solve the Alzheimer’s drug riddle? We could find out within days

    Thursday is shaping up to be one of the most important days for Biogen in recent memory, as the Cambridge biotech prepares to announce data from a trial of a potentially groundbreaking — and extremely lucrative — Alzheimer’s drug. Biogen (BIIB) has a lot riding on the early-stage results for aducanumab, which are scheduled to be announced at the Clinical Trials for Alzheimer's Disease, an annual industry conference in San Diego. The recent failure of a similar Alzheimer’s treatment at Eli Lilly (LLY) cast doubt on the theory that amyloid causes memory loss, and sent Biogen’s share price tumbling .

  • PR Newswire3 hours ago

    Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer

    SAN ANTONIO, Dec. 8, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment. Final data from the Phase 2 trial presented during the official press program at the 2016 San Antonio Breast Cancer Symposium (SABCS) evaluated abemaciclib, both alone or in combination with the non-steroidal aromatase-inhibitor anastrozole, in postmenopausal women with previously untreated early stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. "Lilly is committed to the scientific discovery and development of new therapies that change current standards of cancer care," said Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology.